Predict your next investment

Viome company logo
Corporation
HEALTHCARE | Disease Diagnosis
viome.com

See what CB Insights has to offer

Founded Year

2016

Stage

Series C - II | Alive

Total Raised

$84.96M

Last Raised

$3M | 8 mos ago

About Viome

Viome develops technology that offers visibility into the ecosystem living inside people. Viome blends readings from blood, urine, saliva and stool samples to develop profiles of biochemistry, as well as the microbes in the digestive system. Viome feeds that profile into a smartphone app to offer personalized recommendations for diet and lifestyle.

Viome Headquarter Location

205 108th Ave NE STE 150

Bellevue, Washington, 98004,

United States

505-672-5785

Latest Viome News

09:00 ET Viome Life Sciences Announces Expansion of Collaboration with GSK into new therapeutic interventions for Cancers and Au...

Oct 20, 2021

Expanded collaboration will investigate health interventions using targets based on Viome's discovery platform that analyzes host & microbial interaction at the onset and progression of diseases News provided by Share this article Share this article BELLEVUE, Wash., Oct. 20, 2021 /PRNewswire/ -- Viome Life Sciences, a mission-driven systems biology company aiming to help individuals improve their health, today announced the expansion of its two-year partnership with GSK, a science-led global healthcare company, to expand clinical research activities1 and potential development of new therapeutic interventions within the fields of chronic diseases including autoimmune diseases and cancers. This expansion builds on a previously announced collaboration to research the prevention of specific chronic diseases, leveraging Viome's proprietary microbiome analysis and artificial intelligence platforms and GSK's expertise in immunology. "Most chronic disorders are treated with drugs targeting symptoms and not causes. Viome's unique mRNA technology and state-of-the-art artificial intelligence platform have the potential to find the root causes of specific chronic disorders and cancers. With that critical information and the unique expertise of GSK, we aspire to one day cure these diseases and not just manage the symptoms," said Viome CEO and Founder, Naveen Jain. "We are excited to expand our collaboration with GSK to develop preventative and therapeutic measures for chronic diseases and cancers." The gut microbiome is well recognized for its ability to shape immune fitness, with nearly 70-80% of the immune system housed inside the gut microbiome2 [ PubMed ]. A healthy gut microbiome supports the immune system, which is connected to an individual's overall well-being, weight, energy, mood, and stress. Imbalances in the gut microbiome have been associated with inflammation and chronic diseases ranging from gastrointestinal inflammatory and metabolic conditions to neurological, cardiovascular, and respiratory illnesses3 [ NCBI ]. Through this collaboration, Viome and GSK will examine the connection between the gut microbiome and specific chronic disorders by performing a clinical validation trial. The overall objective of the collaboration aims to advance viable health interventions for the many diseases that continue to threaten individuals, families, and communities around the world. "A better understanding of the interactions between the immune system and microbiome – which have been shown to have a significant impact on human health – has been part of GSK's innovation strategy," said Rino Rappuoli, Head of R&D Vaccines, GSK. "By combining our robust expertise in immunology with Viome's unique technology with its proprietary mRNA analysis and artificial intelligence platform, we look forward to uncovering additional key insights into chronic diseases." Through this partnership, GSK and Viome will continue to examine chronic diseases that are without treatment and will work to develop much-needed new targets for potential interventions. GSK and Viome understand the potential of the gut microbiome to influence an individual's immune system and determine the effectiveness of health interventions and will tap into Viome's extensive research and findings as well as GSK's expertise to accomplish this. Viome is committed to creating a world where chronic diseases could truly be prevented before they cause significant problems. About Viome Life Sciences Viome Life Sciences is a mission-driven systems biology company founded in 2016 to tackle the epidemic of chronic diseases, cancer, and aging. To help individuals improve their health and to better understand the root of chronic diseases, Viome is strategically split into two divisions. Viome Consumer Services is focused on growing its established consumer products including tests, nutrition plans, and supplements. Viome Health Sciences is devoted to advancing its precision diagnostics and therapeutics platform. By conducting mRNA analysis at a mass scale, Viome is digitizing human biology and ultimately stopping the onset and progression of chronic diseases. Recently, Viome garnered FDA Approval for its unique mRNA technology and AI platform to detect cancers and has already successfully developed over 30 predictive models for some of the most prominent chronic diseases. For further information please visit www.viome.com/company About GSK GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/en-gb/about-us . Media Contact

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Viome

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Viome is included in 6 Expert Collections, including Wellness Tech.

W

Wellness Tech

1,209 items

We define wellness tech as companies developing technology to help consumers improve their physical, mental, and social well-being. Companies in this collection play across a wide range of categories, including food and beverage, fitness, personal care, and corporate wellness.

M

Microbiome

274 items

D

Digital Health 150 (2019)

150 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

S

Sleep Health & Wellness

795 items

These companies aim to assess or improve the quantity/quality of sleep, or use sleep data in the monitoring or diagnosis of other health conditions.

G

Game Changers 2020

36 items

Our selected startups are high-momentum companies pioneering technology with the potential to transform society and economies for the better.

S

Self Care & Health

856 items

These startups aim to provide health treatments, diagnosis tools, and products that do not require a prescription or connection with a health professional to enhance personal wellbeing. This includes supplements, women's health maintenance, OTC medicines, and more.

Viome Patents

Viome has filed 1 patent.

The 3 most popular patent topics include:

  • Computational phylogenetics
  • Global health
  • Kuiper quadrangle
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/22/2019

Kuiper quadrangle, Oklahoma counties, Global health, Computational phylogenetics, Phylogenetics

Application

Application Date

4/22/2019

Grant Date

Title

Related Topics

Kuiper quadrangle, Oklahoma counties, Global health, Computational phylogenetics, Phylogenetics

Status

Application

Viome Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Viome Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.